In today’s recent session, 1.26 million shares of the Immuneering Corp (NASDAQ:IMRX) have been traded, and its beta is 0.37. Most recently the company’s share price was $4.03, and it changed around $0.58 or 16.96% from the last close, which brings the market valuation of the company to $145.20M. IMRX at last check was trading at a discount to its 52-week high of $3.87, offering almost 3.97% off that amount. The share price’s 52-week low was $1.00, which indicates that the recent value has risen by an impressive 75.19% since then. We note from Immuneering Corp’s average daily trading volume that its 10-day average is 1.79 million shares, with the 3-month average coming to 1.09 million.
Immuneering Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended IMRX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Immuneering Corp is expected to report earnings per share of -0.42 for the current quarter.
Immuneering Corp (NASDAQ:IMRX) trade information
Instantly IMRX has been showing a green trend so far today with a performance of 16.96% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.05 on recent trading dayincreased the stock’s daily price by 0.49%. The company’s shares are currently up 270.18% year-to-date, but still up 14.31% over the last five days. On the other hand, Immuneering Corp (NASDAQ:IMRX) is 105.87% up in the 30-day period. We can see from the shorts that 0.89 million shares have been sold at a short interest cover period of 3.13 day(s).
The consensus price target as assigned by Wall Street analysts is $13, which translates to bulls needing to increase their stock price by 69.0% from its current value. Analyst projections state that IMRX is forecast to be at a low of $3 and a high of $41.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.45%. Immuneering Corp earnings are expected to increase by 15.16% in 2025, but the outlook is positive 8.73% per year for the next five years.
IMRX Dividends
Immuneering Corp’s next quarterly earnings report is expected to be released on 2025-May-05.
Immuneering Corp (NASDAQ:IMRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 24.12% of Immuneering Corp shares, and 12.55% of them are in the hands of institutional investors. The stock currently has a share float of 16.54%. Immuneering Corp stock is held by 43.0 institutions, with CITADEL ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 6.4083% of the shares, which is about 1.88 million shares worth $2.41 million.
VANGUARD GROUP INC, with 3.6442% or 1.07 million shares worth $1.37 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Health Sciences Fund, Inc. were the top two Mutual Funds as of Mar 31, 2025 . The former held 722.79 shares worth $2.87 million, making up 2.01% of all outstanding shares. On the other hand, T. Rowe Price Health Sciences Fund, Inc. held roughly 431.83 shares worth around $1.71 million, which represents about 1.20% of the total shares outstanding.
